



**Alwin D R Huitema**

**Kontakt**

Alwin D R Huitema

## Publikationen (12)

Mc Laughlin A, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland S, Huitema A, Steeghs N, Müller L, Fuxius S, Illerhaus G, Jörger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. *Cancers (Basel)* 2021; 13

Groenland S, Verheijen R, Jörger M, Mathijssen R, Sparreboom A, Beijnen J, Beumer J, Steeghs N, Huitema A. Precision Dosing of Targeted Therapies Is Ready for Prime Time. *Clin Cancer Res* 2021; 27:6644–6652.

Jacobs B, Deenen M, Joerger M, Rosing H, de Vries N, Meulendijks D, Cats A, Beijnen J, Schellens J, Huitema A. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis. *CPT Pharmacometrics Syst Pharmacol* 2019; 8:940–950.

Crombag M, Koolen S, Wijngaard S, Jörger M, Dorlo T, van Erp N, Mathijssen R, Beijnen J, Huitema A. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. *Pharm Res* 2019; 36:163.

Crombag M, Beijnen J, Mathijssen R, van Erp N, Dorlo T, Schellens J, Jörger M, Wijngaard S, Koolen S, de Vries Schultink A, Huitema A. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. *Pharm Res* 2019; 36:33.

Crombag M, Jörger M, Thürlimann B, Schellens J, Beijnen J, Huitema A. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. *Cancers (Basel)* 2016; 8

Jörger M, Kraff S, Huitema A, Feiss G, Moritz B, Schellens J, Beijnen J, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. *Clin Pharmacokinet* 2012; 51:607–17.

Jörger M, Ferreri A, Krähenbühl S, Schellens J, Cerny T, Zucca E, Huitema A. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. *Br J Clin Pharmacol* 2012; 73:240–7.

Jörger M, Beijnen J, Huitema A, Vincent A, Smits P, Doodeman V, Bard M, Haitjema T, Smit E, Baas P, Burgers S, Schellens J. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. *Cancer* 2011; 118:2466–75.

Jörger M, Hollema H, Féty R, Van der Vijgh W, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers A, Twelves C, Beijnen J, Boddy A, Calvert H, Jodrell D, Huitema A, Richel D, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J, Strocchi E, Martoni A, Sorio R, Sleeboom H, Izquierdo M, Schellens J. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2007; 13:6410–8.

Jörger M, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers A, Twelves C, Beijnen J, Schellens J, Jodrell D, Izquierdo M, Sleeboom H, Huitema A, Richel D, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J, Strocchi E, Martoni A, Sorio R, EORTC-PAMM-NDDG. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. *Clinical pharmacokinetics* 2007; 46:1051–68.

Jörger M, Huitema A, van den Bongard D, Schellens J, Beijnen J. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2006; 12:2150-7.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)